Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic

Relevance. COVID-19 pandemic currently has a significant negative impact on the treatment of patients with oncological pathology, including patients with classic Hodgkin lymphoma. Generalized data on publications on the impact of concomitant pathology on the severity of infection show a significant...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Irina V. Poddubnaya, Elena A. Baryakh, Vladimir I. Vorobyev, E. A. Demina, Nikolay V. Zhukov, K. D. Kaplanov, T. S. Konstantinova, Dmitry V. Motorin, V. V. Ptushkin, Vladislav O. Sarzhevsky, G. S. Tumyan
Formato: article
Lenguaje:RU
Publicado: IP Habib O.N. 2020
Materias:
Acceso en línea:https://doaj.org/article/2004cdd4f9c2412697204e9448c718ca
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:2004cdd4f9c2412697204e9448c718ca
record_format dspace
spelling oai:doaj.org-article:2004cdd4f9c2412697204e9448c718ca2021-11-30T17:03:34ZTherapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic1815-14341815-144210.26442/18151434.2020.2.200206https://doaj.org/article/2004cdd4f9c2412697204e9448c718ca2020-06-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/34878/23270https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Relevance. COVID-19 pandemic currently has a significant negative impact on the treatment of patients with oncological pathology, including patients with classic Hodgkin lymphoma. Generalized data on publications on the impact of concomitant pathology on the severity of infection show a significant increase in the risk of death from infection in male patients, aged 60 years, with the presence of 3 concomitant diseases, among which particularly negative role is played by diseases of the cardiovascular system, diabetes, oncology, chronic lung disease, immunodeficiency conditions. Particularly dangerous is the development of COVID-19 infection in an interval of less than 14 days from the course of antitumor therapy. At the same time, patients with Hodgkin lymphoma require immediate treatment, often associated with toxic, immunosuppressive therapy, frequent visits to the clinic, hospitalizations. International communities have not yet developed clear guidelines for the management of patients with Hodgkins lymphoma. Taking into account the understanding that the circulation of coronoviral infection will continue in the population, the Advisory board on the Problems of Hodgkin Lymphoma Therapy in the COVID-19 Pandemic is highly relevant. Aim. To change and adapt current treatment approaches in the current epidemiological environment. Results. The main directions of the impact of the COVID-19 pandemic on the treatment of patients with cancer pathology, including patients with classical Hodgkin lymphoma, were determined, key problems in the treatment of LC during the COVID-19 pandemic were identified, and measures aimed at reducing the risk for patients were developed. Existing approaches to first-line, relapse/refracturing cHL therapy, including salvage therapy, and auto/allo SCT during the COVID-19 pandemic, have been adapted.Irina V. PoddubnayaElena A. BaryakhVladimir I. VorobyevE. A. DeminaNikolay V. ZhukovK. D. KaplanovT. S. KonstantinovaDmitry V. MotorinV. V. PtushkinVladislav O. SarzhevskyG. S. TumyanIP Habib O.N.articlehodgkin lymphomacovid-19Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 2, Pp 52-55 (2020)
institution DOAJ
collection DOAJ
language RU
topic hodgkin lymphoma
covid-19
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle hodgkin lymphoma
covid-19
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Irina V. Poddubnaya
Elena A. Baryakh
Vladimir I. Vorobyev
E. A. Demina
Nikolay V. Zhukov
K. D. Kaplanov
T. S. Konstantinova
Dmitry V. Motorin
V. V. Ptushkin
Vladislav O. Sarzhevsky
G. S. Tumyan
Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
description Relevance. COVID-19 pandemic currently has a significant negative impact on the treatment of patients with oncological pathology, including patients with classic Hodgkin lymphoma. Generalized data on publications on the impact of concomitant pathology on the severity of infection show a significant increase in the risk of death from infection in male patients, aged 60 years, with the presence of 3 concomitant diseases, among which particularly negative role is played by diseases of the cardiovascular system, diabetes, oncology, chronic lung disease, immunodeficiency conditions. Particularly dangerous is the development of COVID-19 infection in an interval of less than 14 days from the course of antitumor therapy. At the same time, patients with Hodgkin lymphoma require immediate treatment, often associated with toxic, immunosuppressive therapy, frequent visits to the clinic, hospitalizations. International communities have not yet developed clear guidelines for the management of patients with Hodgkins lymphoma. Taking into account the understanding that the circulation of coronoviral infection will continue in the population, the Advisory board on the Problems of Hodgkin Lymphoma Therapy in the COVID-19 Pandemic is highly relevant. Aim. To change and adapt current treatment approaches in the current epidemiological environment. Results. The main directions of the impact of the COVID-19 pandemic on the treatment of patients with cancer pathology, including patients with classical Hodgkin lymphoma, were determined, key problems in the treatment of LC during the COVID-19 pandemic were identified, and measures aimed at reducing the risk for patients were developed. Existing approaches to first-line, relapse/refracturing cHL therapy, including salvage therapy, and auto/allo SCT during the COVID-19 pandemic, have been adapted.
format article
author Irina V. Poddubnaya
Elena A. Baryakh
Vladimir I. Vorobyev
E. A. Demina
Nikolay V. Zhukov
K. D. Kaplanov
T. S. Konstantinova
Dmitry V. Motorin
V. V. Ptushkin
Vladislav O. Sarzhevsky
G. S. Tumyan
author_facet Irina V. Poddubnaya
Elena A. Baryakh
Vladimir I. Vorobyev
E. A. Demina
Nikolay V. Zhukov
K. D. Kaplanov
T. S. Konstantinova
Dmitry V. Motorin
V. V. Ptushkin
Vladislav O. Sarzhevsky
G. S. Tumyan
author_sort Irina V. Poddubnaya
title Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
title_short Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
title_full Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
title_fullStr Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
title_full_unstemmed Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
title_sort therapy of hodgkin lymphoma in russia during the covid-19 pandemic
publisher IP Habib O.N.
publishDate 2020
url https://doaj.org/article/2004cdd4f9c2412697204e9448c718ca
work_keys_str_mv AT irinavpoddubnaya therapyofhodgkinlymphomainrussiaduringthecovid19pandemic
AT elenaabaryakh therapyofhodgkinlymphomainrussiaduringthecovid19pandemic
AT vladimirivorobyev therapyofhodgkinlymphomainrussiaduringthecovid19pandemic
AT eademina therapyofhodgkinlymphomainrussiaduringthecovid19pandemic
AT nikolayvzhukov therapyofhodgkinlymphomainrussiaduringthecovid19pandemic
AT kdkaplanov therapyofhodgkinlymphomainrussiaduringthecovid19pandemic
AT tskonstantinova therapyofhodgkinlymphomainrussiaduringthecovid19pandemic
AT dmitryvmotorin therapyofhodgkinlymphomainrussiaduringthecovid19pandemic
AT vvptushkin therapyofhodgkinlymphomainrussiaduringthecovid19pandemic
AT vladislavosarzhevsky therapyofhodgkinlymphomainrussiaduringthecovid19pandemic
AT gstumyan therapyofhodgkinlymphomainrussiaduringthecovid19pandemic
_version_ 1718406432748994560